Skip to main content
Darren McGuire, MD, Cardiology, Dallas, TX

Darren Keith McGuire MD


Distinguished Teaching Professor, Internal Medicine, Dallas Heart Ball Chair for Heart Disease Research in Women, University of Texas Southwestern Medical Center, Deputy Editor, Circulation

Join to View Full Profile
  • 5323 Harry Hines BoulevardDallas, TX 75390

  • Phone+1 214-645-8000

  • Fax+1 214-645-7269

Dr. McGuire is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Cardiovascular Disease, 1997 - 2001
  • Duke University School of Medicine
    Duke University School of MedicineM.H.S., Clinical Research Training Program, 1998 - 2000
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1993 - 1996
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1993
  • Hendrix College
    Hendrix CollegeB.A., Chemistry, Summa Cum Laude, 1985 - 1989

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1994 - 2026
  • NC State Medical License
    NC State Medical License 1996 - 2002
  • VA State Medical License
    VA State Medical License 1999 - 2000
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Fellow (FESC) European Society of Cardiology
  • Fellow (FAHA) AHA
  • Regents Outstanding Teacher Award University of Texas Board of Regents, 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults with Diabetes  
    Michael C Honigberg, Ravi B Patel, Javed Butler, Darren K Mcguire, JAMA Cardiology
  • Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure  
    Deepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
  • Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes  
    Darren K Mcguire, Samuel Dagogo-Jack, Urszula Masiukiewicz, JAMA Cardiology
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A1C : Glucose management in type 2 diabetes mellitus.
    Goyal A, Kosiborod M, McGuire DK, Garber AJ, American College of Cardiology Foundation Diabetes Self-Assessment Program, Washington, DC, 1/1/2011

Lectures

  • Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
    Scientific Sessions 2008, New Orleans, Louisiana, USA
  • Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
    Scientific Sessions 2007, Orlando, Florida, USA
  • Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
    International Chair on Cardiometabolic Risk, 2nd International Congress on Abdominal Obesity, Buenos
  • Join now to see all

Other

Authored Content

  • Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular DiseaseJune 2020
  • Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart DiseaseNovember 2018
  • Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients with Type 2 DiabetesMarch 2018

Press Mentions

  • Oral Semaglutide Yields Excellent CV Outcomes in High-Risk Type 2 Diabetes
    Oral Semaglutide Yields Excellent CV Outcomes in High-Risk Type 2 DiabetesMay 1st, 2025
  • Novo Nordisk A/S: Rybelsus® (Oral Semaglutide 14 Mg) Demonstrates Superior Reduction in Cardiovascular Events in the SOUL Trial at ACC 2025
    Novo Nordisk A/S: Rybelsus® (Oral Semaglutide 14 Mg) Demonstrates Superior Reduction in Cardiovascular Events in the SOUL Trial at ACC 2025March 31st, 2025
  • Oral Semaglutide Reduces Heart Risks While Helping Patients Move Past ‘Fear of the Needle’
    Oral Semaglutide Reduces Heart Risks While Helping Patients Move Past ‘Fear of the Needle’March 30th, 2025
  • Join now to see all

Grant Support

  • Rosiglitazone VS Placebo: Effect Of CV Performance And Myocardial TriglycerideNational Center For Research Resources2005–2007

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: